Skip to Content
Merck
  • Pharmacokinetics and tissue disposition of meloxicam in beef calves after repeated oral administration.

Pharmacokinetics and tissue disposition of meloxicam in beef calves after repeated oral administration.

Journal of veterinary pharmacology and therapeutics (2015-02-25)
J F Coetzee, R A Mosher, G R Griffith, R Gehring, D E Anderson, B KuKanich, M Miesner
ABSTRACT

The objective of this study was to investigate the pharmacokinetics and tissue disposition of meloxicam after repeated oral administration in calves. Thirteen male British × Continental beef calves aged 4 to 6 months and weighing 297-392 kg received 0.5 mg/kg meloxicam per os once daily for 4 days. Plasma meloxicam concentrations were determined in 8 calves over 6 days after first treatment. Calves were randomly assigned to be euthanized at 5, 10, 15 (n = 3/timepoint), and 19 days (n = 4) after final administration. Meloxicam concentrations were determined in plasma (LOQ= 0.025 μg/mL) and muscle, liver, kidney, and fat samples (LOQ = 2 ng/g) after extraction using validated LC-MS-MS methods. The mean (± SD) Cmax , Cmin , and Caverage plasma meloxicam concentrations were 4.52 ± 0.87 μg/mL, 2.95 ± 0.77 μg/mL, and 3.84 ± 0.81 μg/mL, respectively. Mean (± SD) tissue meloxicam concentrations were highest in liver (226.67 ± 118.16 ng/g) and kidney samples (52.73 ± 39.01 ng/g) at 5 days after final treatment. Meloxicam concentrations were below the LOQ in all tissues at 15 days after treatment. These findings suggest that tissue from meloxicam-treated calves will have low residue concentrations by 21 days after repeated oral administration.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
β-Glucuronidase from Helix pomatia, Type H-2, aqueous solution, ≥85,000 units/mL
Sigma-Aldrich
Piroxicam, ≥98% (TLC)